Author | Peter J. Van Veldhuizen, MD | OncLive

Author | Peter J. Van Veldhuizen, MD

Articles

Dr. Van Veldhuizen Discusses Combination Therapy in RCC

September 19, 2018

Video

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

September 07, 2018

Video

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCC

August 20, 2018

Video

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

July 13, 2018

Video

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.

x